Skip to main content
. 2022 Jan 18;13(2):2927–2942. doi: 10.1080/21655979.2021.2017698

Figure 6.

Figure 6.

miR-665-3p antagomir prevents NAFLD progression via activating AMPKα in vivo. (a-b) The levels of AMPKα phosphorylation. (c) Hepatic ROS levels determined by DCFH-DA probe. (d) MDA levels in the liver. (e) Hepatic IL-1β and IL-6 levels determined by the commercial ELISA kits. (f-g) Hepatic levels of TG, TC and NEFA. (h) Hepatic hydroxyproline levels. (i) Serum ALT and AST levels. All results were expressed as the means ± standard deviations, n = 6 for each group, and *P < 0.05 was considered statistically significant.